Magenta reports MGTA-117 Phase 1/2 data: no DLTs, two patients became transplant eligible

Dianthus Therapeutics, Inc. /DE/

MGTA-117 showed dose-dependent binding and depletion of CD117+ cells; no dose-limiting toxicities observed in 15 patients across Cohorts 1-3.
Two relapsed/refractory AML/MDS patients became eligible for transplant after a single dose of MGTA-117.
Phase 1/2 trial currently enrolling Cohort 4 (0.13 mg/kg); aggregate data including Cohort 4 expected Q1 2023.
Company plans to transition MGTA-117 into transplant-eligible AML/MDS patients in H1 2023 pending regulatory alignment.
MGTA-145 Phase 2 trial in sickle cell disease data now expected H1 2023 due to enrollment delays.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.